Deltex Medical is a British manufacturer of Fluid Management devices, which include the ODM and now ODM+ haemodynamic monitoring systems. From its head office and manufacturing base in Chichester, West Sussex, the company now has subsidiaries in the USA, Canada and Spain.
Deltex’s mission is to benefit patients and healthcare providers by making oesophageal Doppler monitoring (ODM) the standard of care wherever possible. We’re passionate about this because the evidence tells us that use of ODM to guide fluid and drug administration results in better outcomes. Better outcomes for patient, clinician and healthcare provider.
The principle is that by accurately monitoring and managing a patient’s haemodynamic status, the risk of complications is minimised. This means longer life, shorter hospital stay and reduced cost of care.
Deltex’s robust evidence base has been established over many years. It is a compelling story of clinical benefit and cost-effectiveness that is helping the company to achieve system-wide adoption of this unique medical technology.
We’re working hard on our mission across the world. There are already over 3,000 ODM systems in use in hospitals globally with distribution in over 30 countries.
Deltex Medical has been awarded a NICE recommendation for the CardioQ-ODM. ODM Fluid Management is one of the six High Impact Innovations, based on comprehensive evidence which proves that ODM Fluid Management can reduce postoperative complications and reduce length of hospital stay.
Deltex Instruments purchased Doptek in 1989. The two companies ran in parallel until 1st October 1992, when Deltex Medical was officially incorporated. The development of ODM1 was directly led by the MD thesis of Dr Mervyn Singer (now Professor of Intensive Care Medicine at University College Hospital, London) entitled “Continuous Haemodynamic Monitoring by Oesophageal Doppler”.
Developments in the Oesophageal Doppler led to the release of the ODM2 in 1995. This was subsequently followed by upgraded technology in the form of CardioQ (1999) and the CardioQ-ODM (2008). The CardioQ-ODM+, the world’s first fluid management system incorporating both ODM and PPWA technologies, was released in 2012.
In 2001, Deltex Medical passed the £1million turnover mark with sales of £1.3million. Deltex was floated on the AIM market in November 2001.
ODM technology has since received a number of awards and recommendations. These include the NICE MTG3 Guidelines, published in 2011, being named as one of six High Impact Innovations in Innovation, Health and Wealth (2011) as well as a recommendation by the Enhanced Recovery Partnership (2012).
Purpose, Vision & Values
We will validate and deliver innovative healthcare solutions, designed to enhance patient recovery.
- By investing in our products, services and people
- By communicating openly and honestly with our customers and each other
- By changing behaviour and making ODM the system-wide standard of care in intraoperative fluid management
- By cultivating a reputation for expert advice and incomparable support and training
- We will increase profitability and continue to grow the Deltex Medical business.
- With support and understanding, in partnership with the clinician
- With the patient at the heart of our business
- With passion and focus
- With expertise and invention
- With knowledge, experience, and irrefutable evidence
Headquartered in Chichester, Deltex Medical Ltd. is a leader in fluid monitoring systems in the healthcare environment. The company’s technology has been proven to enhance patient care whilst reducing the overall cost to the healthcare provider.
As a pioneer and leader in its field, Deltex is an exciting and dynamic environment place to work with career opportunities across a variety of roles and functions.
Quality Engineer Vacancy
The Quality Assurance and Regulatory Affairs department have a vacancy for a Quality Engineer to join the small department which operates out of the Chichester facility.
The QA/RA Manager is looking for someone with experience in both quality assurance and regulatory affairs within the medical devices specialism, as detailed below:-
- Degree or equivalent in an appropriate academic discipline
- Minimum 3 years Quality Assurance Class II/III (preferably active/software Medical
- BS EN ISO 13485, 21 CFR Part 820, MDD 93/42/EEC, BS EN ISO 14971, EN 62304, IEC 60601, ISO 11135, ISO 14644
Experience of auditing
For further information please contact Marion Lee, Human Resources, on firstname.lastname@example.org
Closing date 31 December 2018
Quality & Regulatory
The development, manufacture and provision of our products and services meet the very highest standards of quality.
Deltex Medical is committed to fulfilling the requirements of: ISO 13485, US FDA Code of Federal Regulations 21 CFR Part 820, Medical Devices Directive 93/42/EEC (as amended) and the Canadian Medical Device Regulations P.C.1998-783 May, 1998. This commitment is demonstrated by maintaining a quality management system that is registered by, and subject to, independent assessment by the appropriate and recognised third party certification bodies.
- ISO 13485:2003 Certificate of Registration
- ISO 13485:2003 Certificate of Registration (CMDCAS Recognised for Canada)
- Full Quality Assurance Certificate (93/42/EEC)
- WEEE Membership Certificate
For further information regarding Quality and Regulatory related to our products please email the team: Q&R
Andy Mears, Chief Executive
Andy joined Deltex Medical in 1989 as an Electronics Engineer. Throughout his career with Deltex Medical, he has held a number of roles, including Product & Production Manager and Operations Director. Andy was appointed as Group Sales Director in 2010, Managing Director 2015 and Chief Executive in 2018.
Jonathan Shaw, Finance Director
Jonathan joined Deltex Medical in 2015. He has spent the majority of his career working at either director or senior manager level in professional accounting and auditing firms most recently with Grant Thornton UK LLP in London and including PricewaterhouseCoopers LLP in Southampton where he was Deltex Medical’s senior audit manager for nearly four years. During his career, Jonathan has undertaken a number of secondments to industry or government and spent almost three years at the Financial Reporting Council.
Dr Graham Lowe, Chief Operating Officer
Graham joined Deltex Medical in 2002 as European Sales and Marketing Director. He was appointed as Marketing & Operations Director in 2006 and Chief Operating Officer in 2016. Graham has previous experience as a Technical Director and European Marketing Director. He has a degree in Zoology & Animal Biology and holds a PhD in Invertebrate Direct Calorimetry.
Peter Rose, International Sales Director
Peter joined Deltex Medical as International Sales Executive in 2002. He has previous experience working in International Business Development, IT Management and Teaching. He has a degree in Mainfield Geography and speaks German, Greek, Spanish and French. He was appointed International Sales Director in 2010.
Tim Taylor, Commercial Director
Tim joined Deltex Medical in 2002 as Regional Sales Manager. In May 2004, he became the UK Sales Manager and was appointed as UK Sales Director in January 2006 and Commercial Director in 2016. Tim previously held a number of Sales and Management roles within patient monitoring and has a degree in Biological Sciences.
Marion Lee, Human Resources Director
Marion joined Deltex Medical in 1987 as Sales Office Manager having previous experience as a Sales Representative. During her career with the Company she has fulfilled a variety of roles including Customer Service Manager, Office Manager & Personal Assistant to the Managing Director and latterly Head of Human Resources. Marion was appointed Human Resources Director in April 2015.
Mark Baylis, Quality and Regulatory Affairs Director
Mark joined Deltex Medical as Regulatory Affairs Manager in March 2015 and was appointed Quality and Regulatory Affairs Director in October 2016. Having started his medical device career in 2003, he has held senior posts in research and development for class III manufacturers before moving into quality and regulatory affairs at a UK based Notified Body in 2011. Mark has a degree in Biomechanical Engineering.